Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Claudins: emerging targets for cancer therapy.

Kominsky SL.

Expert Rev Mol Med. 2006 Aug 4;8(18):1-11. Review.

PMID:
16887048
2.

The structure and function of claudins, cell adhesion molecules at tight junctions.

Tsukita S, Furuse M.

Ann N Y Acad Sci. 2000;915:129-35. Review.

PMID:
11193568
3.

Role of claudins in tumorigenesis.

Swisshelm K, Macek R, Kubbies M.

Adv Drug Deliv Rev. 2005 Apr 25;57(6):919-28. Review.

PMID:
15820559
4.

Claudin-4 as therapeutic target in cancer.

Neesse A, Griesmann H, Gress TM, Michl P.

Arch Biochem Biophys. 2012 Aug 1;524(1):64-70. doi: 10.1016/j.abb.2012.01.009. Epub 2012 Jan 24. Review.

PMID:
22286027
5.
6.

Barriers built on claudins.

Turksen K, Troy TC.

J Cell Sci. 2004 May 15;117(Pt 12):2435-47. Review. Erratum in: J Cell Sci. 2004 Aug 15;117(Pt 18):4341.

7.

Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Hashimoto Y, Yagi K, Kondoh M.

Pflugers Arch. 2017 Jan;469(1):45-53. doi: 10.1007/s00424-016-1878-6. Epub 2016 Sep 15. Review.

PMID:
27629072
8.

Claudins: multifunctional players in epithelial tight junctions and their role in cancer.

Oliveira SS, Morgado-Díaz JA.

Cell Mol Life Sci. 2007 Jan;64(1):17-28. Review.

PMID:
17115119
9.

Claudins and gastric carcinogenesis.

Iravani O, Tay BW, Chua PJ, Yip GW, Bay BH.

Exp Biol Med (Maywood). 2013 Apr;238(4):344-9. doi: 10.1177/1535370213477981. Review.

PMID:
23759999
10.

Tight junction-based epithelial microenvironment and cell proliferation.

Tsukita S, Yamazaki Y, Katsuno T, Tamura A, Tsukita S.

Oncogene. 2008 Nov 24;27(55):6930-8. doi: 10.1038/onc.2008.344. Review.

PMID:
19029935
11.

A novel strategy for a drug delivery system using a claudin modulator.

Kondoh M, Takahashi A, Fujii M, Yagi K, Watanabe Y.

Biol Pharm Bull. 2006 Sep;29(9):1783-9. Review.

12.

Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.

Hashimoto Y, Fukasawa M, Kuniyasu H, Yagi K, Kondoh M.

Ann N Y Acad Sci. 2017 Jun;1397(1):5-16. doi: 10.1111/nyas.13337. Epub 2017 Apr 17. Review.

PMID:
28415141
13.

Tight junctions and their role in cancer metastasis.

Martin TA, Jiang WG.

Histol Histopathol. 2001 Oct;16(4):1183-95. Review.

PMID:
11642738
14.

Tight junctions and bladder cancer (review).

Haynes MD, Martin TA, Jenkins SA, Kynaston HG, Matthews PN, Jiang WG.

Int J Mol Med. 2005 Jul;16(1):3-9. Review.

PMID:
15942671
15.

Role of tight junctions in cell proliferation and cancer.

González-Mariscal L, Lechuga S, Garay E.

Prog Histochem Cytochem. 2007;42(1):1-57. Epub 2007 Feb 27. Review.

PMID:
17502225
16.

[Claudin as a novel target for drug delivery system].

Kondoh M.

Yakugaku Zasshi. 2006 Sep;126(9):711-21. Review. Japanese.

17.

Claudin tight junction proteins: novel aspects in paracellular transport.

Will C, Fromm M, Müller D.

Perit Dial Int. 2008 Nov-Dec;28(6):577-84. Review.

PMID:
18981384
18.

Development and role of tight junctions in the retinal pigment epithelium.

Rizzolo LJ.

Int Rev Cytol. 2007;258:195-234. Review.

PMID:
17338922
19.

Claudin proteins in ovarian cancer.

Morin PJ.

Dis Markers. 2007;23(5-6):453-7. Review.

20.

Emerging roles of claudins in human cancer.

Kwon MJ.

Int J Mol Sci. 2013 Sep 4;14(9):18148-80. doi: 10.3390/ijms140918148. Review.

Supplemental Content

Support Center